January 6, 2025 10:56 AM EST
News Briefing

I-Mab stops work on CD73; Citius to pur­sue ‘strate­gic’ op­tions

ENDPOINTS

Plus, news about Gen­er­al Prox­im­i­ty and PBS Biotech:

I-Mab paus­es CD73 de­vel­op­ment: The com­pa­ny is not mov­ing for­ward with a pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times